ValuEngine upgraded shares of Fibrocell Science (NASDAQ:FCSC) from a sell rating to a hold rating in a report released on Thursday morning, ValuEngine reports.
Separately, Zacks Investment Research upgraded shares of Fibrocell Science from a sell rating to a hold rating in a report on Tuesday, July 16th.
Shares of FCSC traded down $0.03 during mid-day trading on Thursday, hitting $1.82. 27,531 shares of the company traded hands, compared to its average volume of 36,414. Fibrocell Science has a 1-year low of $1.45 and a 1-year high of $3.28. The company has a debt-to-equity ratio of 0.85, a current ratio of 3.59 and a quick ratio of 3.59. The company has a market capitalization of $18.05 million, a P/E ratio of -1.26 and a beta of 1.60. The firm’s 50 day simple moving average is $1.89.
Fibrocell Science (NASDAQ:FCSC) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.07). On average, sell-side analysts predict that Fibrocell Science will post -1.31 earnings per share for the current fiscal year.
An institutional investor recently raised its position in Fibrocell Science stock. Virtu Financial LLC grew its stake in Fibrocell Science Inc (NASDAQ:FCSC) by 90.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,864 shares of the company’s stock after purchasing an additional 18,958 shares during the period. Virtu Financial LLC owned about 0.41% of Fibrocell Science worth $77,000 at the end of the most recent quarter. 28.04% of the stock is currently owned by hedge funds and other institutional investors.
About Fibrocell Science
Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
See Also: Are FAANG stocks a good investment?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.